Companies BeOne Medicines Ltd.
BeOne Medicines (ONC): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me BeOne Medicines Ltd.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers29th pct.Of 16 peer CEOs
CEO pay, last three years
- $18,925,730FY2023
- $20,836,439FY2024
- $17,943,521FY2025
CEO total pay was $17,943,521 in fiscal 2025, down from $20,836,439 in fiscal 2024.
FY2025: salary $1,133,000 · bonus $0 · stock awards $11,249,615 · option awards $3,749,967
Executives and directors
Aaron Rosenberg · CFOChan Lee · General CounselJohn Oyler · CEOLai Wang · PresidentXiaobin Wu · PresidentAlessandro Riva · Independent DirectorAnthony C. Hooper · Independent DirectorCharles L. Sawyers · Independent DirectorCorazon (Corsee) D. Sanders · Independent DirectorElizabeth F. Mooney · Independent DirectorFelix J. Baker · Independent DirectorMargaret Dugan · Independent DirectorMichael Goller · Independent DirectorOlivier Brandicourt · Independent DirectorQingqing Yi · Independent DirectorRanjeev Krishana · Independent DirectorShalini Sharp · Independent DirectorXiaodong Wang · Director
Frequently asked questions
Who was the highest-paid executive at BeOne Medicines Ltd. in fiscal 2025?
As disclosed, Lai Wang (President, Global Head of Research and Development) was the highest-paid executive at BeOne Medicines Ltd. in fiscal 2025, with total compensation of $18,319,310.
How does BeOne Medicines Ltd.'s chief executive pay compare to its disclosed peer group?
As disclosed, John Oyler's total compensation ranked at the 29th percentile of BeOne Medicines Ltd.'s disclosed peer group.
What is BeOne Medicines Ltd.'s CEO-to-median employee pay ratio?
As disclosed, BeOne Medicines Ltd.'s CEO-to-median employee pay ratio was 218:1.
How did shareholders vote on BeOne Medicines Ltd.'s executive compensation?
As disclosed, 94.86% of shareholders supported BeOne Medicines Ltd.'s executive compensation in the latest say-on-pay vote.
How much does BeOne Medicines Ltd. spend in total on board compensation for fiscal 2025?
As disclosed, BeOne Medicines Ltd. reported total board compensation of $6,972,054 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Lai Wang | $659,492 | $0 | $15,249,603 | $1,749,882 | $585,629 | $0 | $74,704 | $18,319,310 |
| President, Global Head of Research and Development | ||||||||
| John Oyler | 1,133,000 | 0 | 11,249,615 | 3,749,967 | 1,676,840 | 0 | 133,829 | 17,943,521 |
| Co-Founder, Chairman and Chief Executive Officer | ||||||||
| Xiaobin Wu | 862,412 | 0 | 7,499,831 | 2,499,932 | 957,277 | 0 | 209,999 | 12,029,451 |
| President and Chief Operating Officer | ||||||||
| Aaron Rosenberg | 660,000 | 0 | 3,870,957 | 1,290,337 | 586,080 | 0 | 21,000 | 6,428,374 |
| Chief Financial Officer | ||||||||
| Chan Lee | 654,000 | 0 | 2,849,678 | 949,876 | 580,752 | 0 | 21,000 | 5,055,306 |
| Senior Vice President, General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Lai Wang | $18,319,310 | $7,402,451 | $7,316,566 | ↑ +10,916,859 |
| John Oyler | 17,943,521 | 20,836,439 | 18,925,730 | ↓ −2,892,918 |
| Xiaobin Wu | 12,029,451 | 11,138,093 | 11,000,169 | ↑ +891,358 |
| Aaron Rosenberg | 6,428,374 | 6,150,178 | — | ↑ +278,196 |
| Chan Lee | 5,055,306 | 4,676,148 | 4,049,366 | ↑ +379,158 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee oversees our compensation and benefit plans and policies, administers our equity incentive plans, reviews, and approves all compensation decisions relating to our executive officers, and makes recommendations to the Board of Directors on compensation for our Chief Executive Officer, Chief Financial Officer, President and Chief Operating Officer, and President, Global Head of Research and Development.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| John Oyler | PSU | 2025-06-10 | 185,062 | 370,123 | — | 740,246 | $7,499,831 |
| Xiaobin Wu | PSU | 2025-06-10 | 123,377 | 246,753 | — | 493,506 | 4,999,975 |
| Aaron Rosenberg | OPTION | 2025-06-10 | — | — | 119,873 | — | 1,290,337 |
| Lai Wang | RSU | 2025-12-31 | — | — | 427,895 | — | 9,999,906 |
| Chan Lee | OPTION | 2025-06-10 | — | — | 88,244 | — | 949,876 |
| Aaron Rosenberg | PSU | 2025-06-10 | 63,681 | 127,361 | — | 254,722 | 2,580,726 |
| Lai Wang | OPTION | 2025-06-10 | — | — | 162,565 | — | 1,749,882 |
| Aaron Rosenberg | RSU | 2025-06-10 | — | — | 63,674 | — | 1,290,231 |
| Lai Wang | RSU | 2025-06-10 | — | — | 86,359 | — | 1,749,899 |
| Xiaobin Wu | RSU | 2025-06-10 | — | — | 123,370 | — | 2,499,856 |
| Lai Wang | PSU | 2025-06-10 | 86,359 | 172,718 | — | 345,436 | 3,499,798 |
| Xiaobin Wu | OPTION | 2025-06-10 | — | — | 232,245 | — | 2,499,932 |
| Chan Lee | RSU | 2025-06-10 | — | — | 46,878 | — | 949,893 |
| John Oyler | OPTION | 2025-06-10 | — | — | 348,374 | — | 3,749,967 |
| John Oyler | RSU | 2025-06-10 | — | — | 185,055 | — | 3,749,784 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| John Oyler | $3,749,784 | $7,499,831 | $3,749,967 | 50.0% |
| Xiaobin Wu | 2,499,856 | 4,999,975 | 2,499,932 | 50.0% |
| Aaron Rosenberg | 1,290,231 | 2,580,726 | 1,290,337 | 50.0% |
| Lai Wang | 11,749,805 | 3,499,798 | 1,749,882 | 20.6% |
| Chan Lee | 949,893 | 0 | 949,876 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Chan Lee | Option | 27,846 | 14.96 | — |
| Chan Lee | RSU | 29,003 | — | 677,800 |
| Chan Lee | RSU | 29,874 | — | 698,155 |
| Wang | RSU | 31,304 | — | 732,486 |
| Chan Lee | PSU | 32,695 | — | 764,082 |
| Chan Lee | RSU | 32,799 | — | 766,513 |
| Aaron Rosenberg | PSU | 39,533 | — | 923,886 |
| Aaron Rosenberg | RSU | 40,573 | — | 948,191 |
| Chan Lee | RSU | 46,878 | — | 1,095,539 |
| Xiaobin Wu | RSU | 46,969 | — | 1,097,666 |
| Wang | RSU | 55,029 | — | 1,286,028 |
| Wang | PSU | 56,329 | — | 1,316,409 |
| Chan Lee | PSU | 62,504 | — | 1,460,718 |
| Aaron Rosenberg | RSU | 63,674 | — | 1,488,061 |
| Wang | RSU | 66,833 | — | 1,561,887 |
| Chan Lee | RSU | 73,567 | — | 1,719,261 |
| Xiaobin Wu | RSU | 78,624 | — | 1,837,443 |
| John Oyler | RSU | 83,512 | — | 1,951,675 |
| Xiaobin Wu | PSU | 84,487 | — | 1,974,461 |
| Aaron Rosenberg | PSU | 84,916 | — | 1,984,487 |
| Wang | RSU | 86,359 | — | 2,018,210 |
| Chan Lee | Option | 88,244 | 20.26 | — |
| Wang | Option | 88,647 | 11.98 | — |
| Aaron Rosenberg | RSU | 88,920 | — | 2,078,060 |
| Chan Lee | Option | 93,587 | 16.41 | — |
| Xiaobin Wu | RSU | 100,243 | — | 2,342,679 |
| Chan Lee | RSU | 105,599 | — | 2,467,849 |
| Wang | PSU | 115,154 | — | 2,691,149 |
| Chan Lee | Option | 115,518 | 12.23 | — |
| John Oyler | RSU | 117,936 | — | 2,756,164 |
| Aaron Rosenberg | Option | 119,873 | 20.26 | — |
| Xiaobin Wu | RSU | 123,370 | — | 2,883,157 |
| Wang | RSU | 126,711 | — | 2,961,236 |
| Aaron Rosenberg | RSU | 127,595 | — | 2,981,895 |
| Xiaobin Wu | Option | 132,977 | 11.98 | — |
| Aaron Rosenberg | Option | 142,740 | 14.06 | — |
| Wang | Option | 162,565 | 20.26 | — |
| John Oyler | PSU | 163,488 | — | 3,820,715 |
| Xiaobin Wu | PSU | 164,502 | — | 3,844,412 |
| John Oyler | RSU | 177,827 | — | 4,155,817 |
| Wang | RSU | 181,857 | — | 4,249,998 |
| John Oyler | RSU | 185,055 | — | 4,324,735 |
| Xiaobin Wu | RSU | 190,060 | — | 4,441,702 |
| Wang | Option | 190,424 | 16.41 | — |
| Wang | Option | 198,913 | 12.23 | — |
| Xiaobin Wu | Option | 232,245 | 20.26 | — |
| John Oyler | Option | 236,015 | 11.98 | — |
| John Oyler | PSU | 246,753 | — | 5,766,618 |
| Xiaobin Wu | RSU | 272,805 | — | 6,375,453 |
| Xiaobin Wu | Option | 285,402 | 16.41 | — |
| Xiaobin Wu | Option | 298,376 | 12.23 | — |
| John Oyler | Option | 348,374 | 20.26 | — |
| John Oyler | RSU | 367,848 | — | 8,596,608 |
| Wang | RSU | 427,895 | — | 9,999,906 |
| John Oyler | Option | 506,298 | 16.41 | — |
| John Oyler | RSU | 528,060 | — | 12,340,762 |
| John Oyler | Option | 577,551 | 12.23 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Xiaodong WangNot independent · Scientific Advisory (Co-Chair) | $0 | $0 | $0 | $0 | $4,249,830 | $4,249,830 |
| Anthony C. HooperIndependent · Audit · Nominating and Corporate Governance (Chair) · Commercial and Medical Affairs Advisory (Chair) | 128,341 | 199,834 | 199,954 | 0 | 0 | 528,129 |
| Shalini SharpIndependent · Audit (Chair) · Nominating and Corporate Governance | 125,377 | 199,834 | 199,954 | 0 | 0 | 525,165 |
| Margaret DuganIndependent · Compensation (Chair) · Scientific Advisory · Commercial and Medical Affairs Advisory | 115,000 | 199,834 | 199,954 | 0 | 0 | 514,788 |
| Corazon (Corsee) D. SandersIndependent · Audit · Scientific Advisory · Commercial and Medical Affairs Advisory · Not standing for re-election | 102,500 | 199,834 | 199,954 | 0 | 0 | 502,288 |
| Alessandro RivaIndependent · Nominating and Corporate Governance · Scientific Advisory (Co-Chair) | 95,000 | 199,834 | 199,954 | 0 | 0 | 494,788 |
| Olivier BrandicourtIndependent · Audit · Commercial and Medical Affairs Advisory | 92,500 | 199,834 | 199,954 | 0 | 0 | 492,288 |
| Ranjeev KrishanaIndependent · Compensation · Commercial and Medical Affairs Advisory · Not standing for re-election | 90,000 | 199,834 | 199,954 | 0 | 0 | 489,788 |
| Qingqing YiIndependent · Compensation · Scientific Advisory · Not standing for re-election | 90,000 | 199,834 | 199,954 | 0 | 0 | 489,788 |
| Michael GollerIndependent · Nominating and Corporate Governance · Scientific Advisory · Not standing for re-election | 85,000 | 199,834 | 199,954 | 0 | 0 | 484,788 |
| Charles L. SawyersIndependent · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| Elizabeth F. MooneyIndependent · Audit · Compensation · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
| John V. OylerEmployee director · Board Chair | 0 | 0 | 0 | — | 0 | 0 |
| Felix J. BakerIndependent · Newly elected | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $65,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 35,000 / 30,000 / 20,000 |
| Stock ownership guideline | The Compensation Committee has adopted share ownership guidelines applicable to our non-employee directors, the terms of which are described above under “Share Ownership Guidelines.” |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $923,718 |
| Equity awards (grant-date value) | $1,798,506 |
| All other compensation | $4,249,830 |
| Total cost of the board | $6,972,054 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names BeOne Medicines as a peer
Companies that benchmark against ONC
7 companies name ONC as a compensation peer
The list of companies that name ONC as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
ALNY Alnylam Pharmaceuticals, Inc.NBIX Neurocrine Biosciences, Inc.REGN Regeneron Pharmaceuticals, Inc.BIIB Biogen Inc.UTHR United Therapeutics CorporationBMRN BioMarin Pharmaceutical, Inc.MRNA Moderna, Inc.VRTX Vertex Pharmaceuticals Inc.SRPT Sarepta Therapeutics, Inc.JAZZ Jazz Pharmaceuticals plcEXEL Exelixis, Inc.JAZZ Jazz Pharmaceuticals plcSRPT Sarepta Therapeutics, Inc.GILD Gilead Sciences, Inc.AMGN Amgen Inc.INCY Incyte Corporation
Peer reciprocity
The companies BeOne Medicines Ltd. names as compensation peers that name it back in their own disclosed peer groups.
Alnylam Pharmaceuticals, Inc. (ALNY)104Neurocrine Biosciences, Inc. (NBIX)105BioMarin Pharmaceutical, Inc. (BMRN)106Moderna, Inc. (MRNA)107Incyte Corporation (INCY)108
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | Gilead Sciences, Inc. | 2025 | Daniel O'Day | 1,795,192 | 15,238,402 | 4,500,060 | 4,848,120 | 28,437,198 |
| 4 | Amgen Inc. | 2025 | Robert Bradway | 1,925,409 | 12,599,589 | 5,399,996 | 3,907,000 | 24,693,120 |
| 5 | Biogen Inc. | 2025 | Christopher Viehbacher | 1,727,885 | 18,368,875 | 0 | 3,190,875 | 23,646,004 |
| 6 | BioMarin Pharmaceutical, Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 7 | Vertex Pharmaceuticals Inc. | 2025 | Reshma Kewalramani | 1,600,000 | 15,002,270 | 0 | 4,118,640 | 21,144,261 |
| 8 | Moderna, Inc. | 2025 | Stéphane Bancel | 1,677,739 | 6,897,455 | 6,897,425 | 4,302,360 | 19,932,217 |
| 9 | Jazz Pharmaceuticals plc | 2025 | Renee Gala | 1,003,269 | 16,138,433 | 0 | 1,980,000 | 19,151,558 |
| 10 | United Therapeutics Corporation | 2025 | Martine Rothblatt | 1,545,005 | 6,067,990 | 6,075,804 | 4,281,875 | 18,038,972 |
| 11 | BeOne Medicines Ltd. | 2025 | John Oyler | 1,133,000 | 11,249,615 | 3,749,967 | 1,676,840 | 17,943,521 |
| 12 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 13 | Neurocrine Biosciences, Inc. | 2025 | Kyle Gano | 920,000 | 5,750,023 | 5,750,006 | 0 | 13,448,935 |
| 14 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 15 | Regeneron Pharmaceuticals, Inc. | 2025 | Leonard Schleifer | 1,979,922 | — | — | 3,682,655 | 7,280,549 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| BeOne Medicines Ltd. | 148% | PSU 50 · Options 25 · RSU 25 | No | Pay Governance |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| Amgen Inc. | 136.0% | PSU 50 · Options 30 · RSU 20 | Yes — relative TSR | Frederic W. Cook & Co., Inc. (FW Cook) |
| Biogen Inc. | 127% | PSU 60 · RSU 40 | Yes | Pay Governance |
| BioMarin Pharmaceutical, Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Gilead Sciences, Inc. | 180% | PSU 50 · Option 25 · RSU 25 | Yes — Relative TSR | FW Cook |
| Incyte Corporation | 138.6% | PSU 60 · RSU 20 · Option 20 | Yes — relative total shareholder return (TSR) | Aon |
| Jazz Pharmaceuticals plc | 150% | PSU 50 · RSU 50 | Yes — Relative TSR | Aon |
| Moderna, Inc. | 170% | PSU 50 · Options 50 | No | Pay Governance LLC |
| Neurocrine Biosciences, Inc. | 105% | Option 50 · PRSU 30 · RSU 20 | No | Frederic W. Cook & Co., Inc. |
| Regeneron Pharmaceuticals, Inc. | 155% | Options 60 · RSU 40 | not disclosed | Pay Governance LLC |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| United Therapeutics Corporation | 221% | PSO 50 · PSU 50 | No | Aon |
| Vertex Pharmaceuticals Inc. | not disclosed | PSU 55 · RSU 45 | No | Pearl Meyer |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 975,327,100 | 52,877,460 | 32,815,949 | 94.86% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-11 | 94.86%a |
a. Approved under the standard stated in the filing — “Advisory Vote on the Compensation of the Named Executive Officers Vote Required and Board of Directors' Recommendation Approval of Proposal 10 requires the affirmative vote of a simple majority of the votes cast at the Annual Meeting. || Abstentions: Broker non-votes, blank ballots, invalid ballots and abstentions with respect to Proposal 10 will not be treated as votes cast for this purpose and, therefore, will not affect the outcome of the vote.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 218 : 1 |
|---|---|
| CEO total compensation | $17,943,521 |
| Median employee compensation | $82,226 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Xiaobin Wu | President and COO | 2026-08-25 | D | 280 | $380 | $106,400 | Common | Form 4 ↗ |
| Titus B. Ball | Principal Accounting Officer | 2026-09-01 | D | 132 | 356 | 46,974 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-08 | D | 403,351 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-08 | D | 6,278 | 351 | 2,205,174 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-08 | D | 6,569 | 350 | 2,300,951 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-08 | D | 10,688 | 349 | 3,733,141 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-08 | A | 31,027 | 37 | 1,144,896 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-08 | D | 1,721 | 348 | 598,930 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-08 | D | 1,517 | 347 | 526,993 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-08 | D | 2,841 | 346 | 983,433 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-08 | D | 1,181 | 345 | 407,897 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-08 | D | 7,492 | 348 | 2,609,573 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-14 | D | 30,768 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-14 | A | 30,768 | 37 | 1,133,185 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-14 | A | 30,768 | 37 | 1,133,185 | Common | Form 4 ↗ |
| BAKER BROS. ADVISORS LP | Director | 2026-09-14 | D | 30,768 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 3,499 | 363 | 1,270,485 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 4,239 | 362 | 1,535,228 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 403,364 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 738 | 367 | 271,012 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 14,525 | 367 | 5,324,550 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 3,419 | 364 | 1,244,747 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 2,241 | 361 | 809,120 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 40 | 359 | 14,366 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 120 | 359 | 43,045 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 160 | 357 | 57,115 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | A | 31,028 | 37 | 1,144,933 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-09-28 | D | 2,047 | 366 | 748,891 | Common | Form 4 ↗ |
| Chan Lee | SVP, General Counsel | 2026-09-30 | D | 1,115 | 375 | 418,125 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-13 | D | 6,558 | 353 | 2,312,148 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-13 | A | 31,027 | 37 | 1,144,896 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-13 | D | 1,260 | 353 | 445,078 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-13 | D | 403,351 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-13 | D | 5,681 | 351 | 1,996,280 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-13 | D | 10,361 | 350 | 3,631,262 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-13 | D | 7,167 | 350 | 2,505,306 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 403,364 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 6,903 | 366 | 2,528,020 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 3,965 | 365 | 1,448,927 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 2,841 | 364 | 1,033,980 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 8,148 | 363 | 2,959,696 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 2,331 | 362 | 844,639 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 320 | 361 | 115,404 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 1,280 | 360 | 460,444 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 1,681 | 359 | 603,052 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 1,239 | 358 | 442,990 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 1,440 | 356 | 512,087 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | D | 880 | 356 | 312,892 | Common | Form 4 ↗ |
| Xiaodong Wang | Director | 2026-10-27 | A | 31,028 | 37 | 1,144,933 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (108 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Lai Wang. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 18,319,310. View filing ↗
- Section 01, John Oyler. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table” · page 127. As printed: 17,943,521. View filing ↗
- Section 01, Xiaobin Wu. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 12,029,451. View filing ↗
- Section 01, Aaron Rosenberg. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 6,428,374. View filing ↗
- Section 01, Chan Lee. DEF 14A, filed 2026-04-28. Section “Summary Compensation Table”. As printed: 5,055,306. View filing ↗
- Section 03, John Oyler PSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Xiaobin Wu PSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Aaron Rosenberg OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Lai Wang RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Chan Lee OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Aaron Rosenberg PSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Lai Wang OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Aaron Rosenberg RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Lai Wang RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Xiaobin Wu RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Lai Wang PSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Xiaobin Wu OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Chan Lee RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, John Oyler OPTION. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, John Oyler RSU. DEF 14A, filed 2026-04-28. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-28. Section “CEO Pay Ratio”. As printed: 218 : 1. View filing ↗
- Section 08, Xiaodong Wang. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 4,249,830. View filing ↗
- Section 08, Anthony C. Hooper. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 528,129. View filing ↗
- Section 08, Shalini Sharp. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 525,165. View filing ↗
- Section 08, Margaret Dugan. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 514,788. View filing ↗
- Section 08, Corazon (Corsee) D. Sanders. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 502,288. View filing ↗
- Section 08, Alessandro Riva. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 494,788. View filing ↗
- Section 08, Olivier Brandicourt. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 492,288. View filing ↗
- Section 08, Ranjeev Krishana. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 489,788. View filing ↗
- Section 08, Qingqing Yi. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 489,788. View filing ↗
- Section 08, Michael Goller. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 484,788. View filing ↗
- Section 08, Charles L. Sawyers. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Elizabeth F. Mooney. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, John V. Oyler. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Felix J. Baker. DEF 14A, filed 2026-04-28. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Xiaobin Wu 2026-08-25. Form 4, filed 2026-08-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Titus B. Ball 2026-09-01. Form 4, filed 2026-09-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, BAKER BROS. ADVISORS LP 2026-09-14. Form 4, filed 2026-09-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-09-28. Form 4, filed 2026-09-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Chan Lee 2026-09-30. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-13. Form 4, filed 2026-10-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xiaodong Wang 2026-10-27. Form 4, filed 2026-10-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 94.86% (votes for as printed: 975,327,100). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 923,718 + equity 1,798,506 + all other 4,249,830 = 6,972,054, summed across the director compensation table rows.
- Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
- Incyte Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. View filing ↗
- Gilead Sciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Gilead Sciences, Inc.'s own proxy. As printed: 28,437,198. View filing ↗
- Amgen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Amgen Inc.'s own proxy. As printed: 24,693,120. View filing ↗
- Biogen Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Biogen Inc.'s own proxy. As printed: 23,646,004. View filing ↗
- BioMarin Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in BioMarin Pharmaceutical, Inc.'s own proxy. As printed: 21,927,563. View filing ↗
- Vertex Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Vertex Pharmaceuticals Inc.'s own proxy. As printed: 21,144,261. View filing ↗
- Moderna, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-16. CEO total compensation as printed in Moderna, Inc.'s own proxy. As printed: 19,932,217. View filing ↗
- Jazz Pharmaceuticals plc, Section 10b CEO total. DEF 14A, filed 2026-06-08. CEO total compensation as printed in Jazz Pharmaceuticals plc's own proxy. As printed: 19,151,558. View filing ↗
- United Therapeutics Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in United Therapeutics Corporation's own proxy. As printed: 18,038,972. View filing ↗
- BeOne Medicines Ltd. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in BeOne Medicines Ltd.'s own proxy. As printed: 17,943,521. View filing ↗
- Alnylam Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. View filing ↗
- Neurocrine Biosciences, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Neurocrine Biosciences, Inc.'s own proxy. As printed: 13,448,935. View filing ↗
- Sarepta Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. View filing ↗
- Regeneron Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Regeneron Pharmaceuticals, Inc.'s own proxy. As printed: 7,280,549. View filing ↗
- Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity. DEF 14A. Alnylam Pharmaceuticals, Inc. names BeOne Medicines Ltd. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Neurocrine Biosciences, Inc. reciprocity. DEF 14A. Neurocrine Biosciences, Inc. names BeOne Medicines Ltd. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, BioMarin Pharmaceutical, Inc. reciprocity. DEF 14A. BioMarin Pharmaceutical, Inc. names BeOne Medicines Ltd. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Moderna, Inc. reciprocity. DEF 14A. Moderna, Inc. names BeOne Medicines Ltd. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Incyte Corporation reciprocity. DEF 14A. Incyte Corporation names BeOne Medicines Ltd. in its own disclosed peer group (read from its most recent proxy). View filing ↗